Shareholders Approve Zalm Therapeutics Share Issue

Shareholders Approve Zalm Therapeutics Share Issue – Set Stage to Accelerate Market Entry and Expand Patient Choice

At a Special Meeting held online today, Wednesday 19 January 2022, Rua Bioscience shareholders voted in favour of Rua acquiring Zalm Therapeutics. Shareholders were asked to vote on a resolution being:

That the issue of:
• 8,140,000 new ordinary shares (Initial Shares); and
• 16,280,000 equity securities having the right to convert into ordinary shares on achievement of the milestones described in the explanatory notes (Performance Shares)
to the shareholders of Zalm Therapeutics Limited (which may together eventually result in those subscribers holding 28,735,632 fully paid ordinary shares in the Company) be approved for all purposes, including for the purposes of NZX Listing Rule 4.2.1(a).

As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolution was passed by the required majority, and the result of the voting is attached.

Authorised by:
Hamish White
CFO and Company Secretary
[email protected]

For further information:
Kerry Donovan
Communications Manager
[email protected]

---

Announcement PDF